Cargando…
2359. Relative effectiveness of mRNA-1273, BNT162b2, and Ad26.COV2.S vaccines in adults at higher risk for severe COVID-19 outcomes
BACKGROUND: Older age ( > 65 years) and underlying chronic medical conditions are risk factors associated with severe COVID-19 outcomes. In this study, we evaluated the relative vaccine effectiveness (rVE) of a primary series of mRNA-1273 (2 doses) versus BNT162b2 (2 doses) or Ad26.COV2.S (1 dose...
Autores principales: | Nguyen, Van Hung, Boileau, Catherine, Bogdanov, Alina, Zeng, Ni, Bonafede, Mac, Ducruet, Thierry, Rosen, Andrew M, Martin, David, Esposito, Daina, Van de Velde, Nicolas, Kopel, Hagit, Mansi, James |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10676982/ http://dx.doi.org/10.1093/ofid/ofad500.1980 |
Ejemplares similares
-
Relative Effectiveness of BNT162b2, mRNA-1273, and Ad26.COV2.S Vaccines and Homologous Boosting in Preventing COVID-19 in Adults in the US
por: Hung Nguyen, Van, et al.
Publicado: (2023) -
Comparative Effectiveness of Bivalent (Original/Omicron BA.4/BA.5) COVID-19 Vaccines in Adults
por: Kopel, Hagit, et al.
Publicado: (2023) -
Real-world comparative effectiveness of mRNA-1273 and BNT162b2 vaccines among immunocompromised adults identified in administrative claims data in the United States
por: Mues, Katherine E., et al.
Publicado: (2022) -
Effectiveness of mRNA-1273 and BNT162b2 Vaccines in Qatar
por: Abu-Raddad, Laith J., et al.
Publicado: (2022) -
Comparative Immunogenicity and Effectiveness of mRNA-1273, BNT162b2, and Ad26.COV2.S COVID-19 Vaccines
por: Naranbhai, Vivek, et al.
Publicado: (2021)